ArticleCancers2021
Renal Safety of [
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023Guideline
- Pooled it
- Could we reduce renal toxicity of [European journal of nuclear medicine and molecular imaging · 2026Article
- Quantifying the Renal Impact of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Dosimetry of [EJNMMI research · 2026Article
- Frailty and [Theranostics · 2026Review
- Innovative Peptide Therapeutics in the Pipeline: Transforming Cancer Detection and Treatment.International journal of molecular sciences · 2025Review
- Impact of extended [European journal of nuclear medicine and molecular imaging · 2025Article
- Mathematic Modeling of Tumor Growth During [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancer management and research · 2025Review
- Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy.Frontiers in oncology · 2025Review
- Role of Lutetium Radioligand Therapy in Prostate Cancer.Cancers · 2024Review
- A Comparison ofDiagnostics (Basel, Switzerland) · 2024Article
- The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [Breast cancer research : BCR · 2024Article
- Article
- Extended therapy with [European journal of nuclear medicine and molecular imaging · 2023Article
- Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals.Pharmaceutics · 2023Review
- 2022 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel, Switzerland) · 2023Article
- PSMA-targeted therapy for non-prostate cancers.Frontiers in oncology · 2023Review
- Pharmacological Optimization of PSMA-Based Radioligand Therapy.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.